SF3B1 and B-cell chronic lymphocytic leukemia: Some of these novel drivers, such as SF3B1 and NOTCH1 mutations, identified patients at higher risk of disease progression as well as disease recurrence after chemotherapy-based CLL therapy (34, 36, 37).